Stock ScreenerStock IdeasZen Ratings + Top Analysts
Stocks With a Zen Rating of A + Top Analyst consensus of Strong Buy + Large Upside in Target Price: Dec 24, 2025
The 2 best sources of winning stocks is the Zen Ratings and our analysis of Top Analysts from Wall Street. Now we have combined them together in a best of both worlds approach to find stocks with the best upside potential.

Zen Rating: A
Upside/Downside: Large Upside
Top Analysts Consensus: Strong Buy
Ticker
Company
Zen Rating
Growth
Market Cap
Revenue
EBITDA
Earnings
EPS
Rev. Y/Y
Rev. 5Y
Earn. Y/Y
Earn. 5Y
Earnings Date
ALNY
ALNYLAM PHARMACEUTICALS INC
AA$52.67B$3.21B$151.92M$43.57M$0.3153.24%51.59%N/AN/A2026-02-12
ONC
BEONE MEDICINES LTD
AA$34.60B$4.97B$318.03M$68.55M$0.0549.92%79.66%N/AN/A
FIX
COMFORT SYSTEMS USA INC
AA$34.05B$8.32B$1.21B$837.62M$23.6727.71%23.67%80.55%43.80%
NVT
NVENT ELECTRIC PLC
AA$16.78B$3.58B$1.08B$602.10M$3.6721.54%11.85%5.76%N/A2026-02-05
NBIX
NEUROCRINE BIOSCIENCES INC
AB$14.68B$2.68B$679.20M$428.00M$4.3119.61%20.82%11.66%33.67%2026-02-11
VTRS
VIATRIS INC
AB$13.84B$14.12B-$598.90M-$3.69B-$3.09-6.14%4.17%N/AN/A
JAZZ
JAZZ PHARMACEUTICALS PLC
AB$10.30B$4.16B$182.64M-$368.48M-$5.994.14%12.77%N/AN/A
SGHC
SUPER GROUP (SGHC) LTD
AC$6.05B$2.50BN/A$250.52M$0.5037.25%N/A2,420.00%N/A
GTES
GATES INDUSTRIAL CORP PLC
AB$5.73B$3.42B$672.10M$236.70M$0.92-0.75%4.63%9.52%29.77%
CPA
COPA HOLDINGS SA
AC$5.02B$3.45B$1.12B$608.11M$14.55-0.31%4.94%13.85%20.15%2026-02-18
UGP
ULTRAPAR HOLDINGS INC
AB$4.03B$22.98B$1.18B$406.67M$0.37-16.54%0.81%-24.07%32.18%
CALX
CALIX INC
AA$3.67B$933.69M$10.21M-$7.25M-$0.104.89%13.70%N/AN/A2026-01-26
SPNT
SIRIUSPOINT LTD
AA$2.62B$2.84B$339.10M$182.30M$1.667.87%30.11%0.00%32.93%2026-02-19
HCI
HCI GROUP INC
AA$2.54B$816.58M$301.16M$203.94M$17.268.75%21.90%16.23%33.77%
EXTR
EXTREME NETWORKS INC
AA$2.24B$1.18B$65.83M$8.65M$0.0714.31%4.93%N/AN/A2026-02-04
ANIP
ANI PHARMACEUTICALS INC
AA$1.81B$826.88M$165.21M$39.01M$1.7148.87%32.93%N/AN/A
BLBD
BLUE BIRD CORP
AC$1.65B$1.48B$194.43M$127.72M$4.019.87%10.98%22.63%54.88%2026-02-11
BCRX
BIOCRYST PHARMACEUTICALS INC
AA$1.59B$599.82M$83.87M-$8.78M-$0.0545.38%62.14%N/AN/A
DNOW
DNOW INC
AC$1.43B$2.43B$165.00M$95.00M$0.893.18%4.64%-52.66%N/A2026-02-12
ANAB
ANAPTYSBIO INC
AB$1.39B$169.47M-$82.14M-$84.63M-$2.74196.42%56.59%N/AN/A
DFIN
DONNELLEY FINANCIAL SOLUTIONS INC
AC$1.23B$750.80M$119.00M$32.50M$1.11-6.40%-3.00%-66.47%17.77%2026-02-24
TBLA
TABOOLACOM LTD
AB$1.20B$1.88B$137.29M$25.29M$0.0810.96%N/AN/AN/A2026-02-19
NUTX
NUTEX HEALTH INC
AC$1.18B$981.20M$227.40M$120.57M$21.20236.03%N/AN/AN/A
CRTO
CRITEO SA
AC$1.07B$1.96B$219.28M$168.06M$3.120.53%-1.06%71.43%23.41%2026-02-11
TBPH
THERAVANCE BIOPHARMA INC
AC$940.99M$80.33M$55.37M$29.34M$0.5827.12%-0.56%N/AN/A
ORGO
ORGANOGENESIS HOLDINGS INC
AA$729.74M$465.22M$18.04M-$13.39M-$0.122.24%8.73%N/AN/A
BWMX
BETTERWARE DE MEXICO SAPI DE CV
AB$515.71M$770.18M$145.14M$55.54MN/A11.00%26.08%N/AN/A
VREX
VAREX IMAGING CORP
AA$502.90M$844.60M-$1.00M-$70.30M-$1.704.14%2.73%N/AN/A
LE
LANDS' END INC
AB$434.44M$1.31B$86.84M$11.75M$0.37-8.47%-1.79%N/A-5.84%
EGHT
8X8 INC
AB$273.12M$721.38M$51.06M-$5.93M-$0.040.25%8.00%N/AN/A2026-02-04
OPRX
OPTIMIZERX CORP
AA$237.48M$109.51M$11.65M$34.00k$0.0024.18%26.16%N/AN/A
ELMD
ELECTROMED INC
AC$228.11M$66.22M$12.05M$8.20M$0.9716.05%15.53%29.33%17.13%2026-02-17
LTRX
LANTRONIX INC
AB$226.31M$118.29M-$5.00M-$10.27M-$0.26-26.85%12.97%N/AN/A
CXDO
CREXENDO INC
AB$202.82M$66.35M$7.94M$4.36M$0.1512.91%33.25%150.00%16.47%
INFU
INFUSYSTEM HOLDINGS INC
AC$183.84M$141.05M$24.16M$5.52M$0.266.23%8.37%333.33%-7.31%

Upgrade to Premium to View More

Use the proven Zen Ratings quant model to find stocks with high potential to beat the market. Stocks Zen-Rated "A" have beaten the market by +32.52% annually. Learn More

Already have access to Premium? Sign In
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.